Log In Get Started
Press Releases July 28, 2026 07:00 AM

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

OKYO Pharma's Chief Scientific Officer Increases Stake Amid Upcoming Phase 3 Trial

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
OKYO

OKYO Pharma Limited announces that Chief Scientific Officer Raj Patil purchased additional shares, increasing his total holdings ahead of the company's planned Phase 3 pivotal clinical trial for urcosimod targeting neuropathic corneal pain. This insider buying signals confidence in the company’s clinical pipeline and growth prospects.

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
OKYO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Raj Patil, Chief Scientific Officer, bought 3,363 shares at $1.49 each, increasing total holdings to 20,030 shares.
  • OKYO Pharma is preparing to initiate a global Phase 3 clinical trial enrolling approximately 111 patients for urcosimod in the second half of 2026.
  • The company focuses on treatments for neuropathic corneal pain and anterior segment eye diseases, areas within the biopharmaceutical and ophthalmology sectors.

LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company’s ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary shares.

About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: [email protected]


Risks

  • Clinical trial outcomes are uncertain and could negatively impact stock and development trajectory if results are unfavorable.
  • Insider buying, while positive, does not guarantee success and may be perceived as limited only to internal confidence.
  • Market reception of novel therapies for neuropathic corneal pain is uncertain, affecting commercialization potential and investor sentiment.

More from Press Releases

FactSet expands partnership with RepRisk to strengthen sustainable investing solutions suite for clients Jul 28, 2026 GrowGeneration Announces Second Quarter 2026 Earnings Release Conference Call for August 11, 2026 Jul 28, 2026 Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce Jul 28, 2026 Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences Jul 28, 2026 Enlivex Announces $400,000,000 Private Placement Jul 28, 2026